Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × dalotuzumab × Clear all

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lung Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Rectal Neoplasms 1 Pleural Effusion 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Insulin-Like Growth Factor I, Resistance To 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Trastuzumab 266 Paclitaxel 228 Cyclophosphamide 223 Docetaxel 210 Capecitabine 162 Letrozole 143 Carboplatin 142 Fulvestrant 132 Doxorubicin 130 Bevacizumab 111 Anastrozole 92 Tamoxifen 88 Vinorelbine 83 exemestane 78 Gemcitabine 78 Epirubicin 78 Lapatinib 73 pertuzumab 71 Radiotherapy 65 Albumin-Bound Paclitaxel 65 pembrolizumab 63 palbociclib 57 eribulin 52 Cisplatin 50 130-nm albumin-bound paclitaxel 49 Everolimus 44 Taxes 39 Neoadjuvant Therapy 38 Goserelin 37 pyrotinib 34

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01605396 2019-03-25

MK-8669-064

Merck Sharp & Dohme LLC

Phase 2 Completed

80 enrolled 13 charts

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡